auro-valganciclovir tablet
auro pharma inc - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides
valganciclovir- valganciclovir hydrochloride powder, for solution
american health packaging - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - treatment of cytomegalovirus (cmv) retinitis: valganciclovir for oral solution is indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)]. prevention of cmv disease: valganciclovir for oral solution is indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1)]. prevention of cmv disease: valganciclovir for oral solution is indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2)]. valganciclovir for oral solution is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adv
valganciclovir kp valganciclovir (as hydrochloride) 450 mg film coated tablet bottle
juno pharmaceuticals pty ltd - valganciclovir hydrochloride -
valganciclovir amneal valganciclovir (as hydrochloride) 450 mg film coated tablet bottle
juno pharmaceuticals pty ltd - valganciclovir hydrochloride -
valganciclovir ch valganciclovir (as hydrochloride) 450 mg film coated tablet bottle
juno pharmaceuticals pty ltd - valganciclovir hydrochloride -
valganciclovir alphapharm valganciclovir (as hydrochloride) 450 mg film-coated tablet bottle
alphapharm pty ltd - valganciclovir hydrochloride -
valcyte valganciclovir (as hydrochloride) 50 mg/ml powder for oral solution bottle
pharmaco australia ltd - valganciclovir, quantity: 5 g - solution, powder for - excipient ingredients: mannitol; fumaric acid; sodium benzoate; saccharin sodium; povidone; flavour - valcyte is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids). valcyte is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.
valcyte 450 mg film-coat. tabl.
cheplapharm arzneimittel gmbh - valganciclovir hydrochloride 496,3 mg - eq. valganciclovir 450 mg - film-coated tablet - 450 mg - valganciclovir hydrochloride 496.3 mg - valganciclovir
valganciclovir 450mg film-coated tablets
milpharm limited - valganciclovir - film-coated tablets - 450mg - antivirals for systemic use, nucleosides and nucleotides excl. reverse transcriptase inhibitors - it is indicated for the induction and maintenance treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids) and for the prevention of cmv disease in cmvnegative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a cmv-positive donor.
valganciclovir sandoz 450 mg film-coat. tabl.
sandoz sa-nv - valganciclovir hydrochloride 496,3 mg - eq. valganciclovir 450 mg - film-coated tablet - valganciclovir